TB-500

Thymosin beta-4 is one of the most abundant peptides in mammalian cells, and TB-500 is the synthetic form used in research. Its function is fundamental rather than specialised: it governs actin availability, which in turn controls how cells move. That places it upstream of almost every repair process, which is why the literature spans cardiac, corneal, dermal and neural models rather than concentrating in a single area. FAB Research supplies TB-500 in a 20mg pre-filled metered research pen for scientific and laboratory investigation.

Sequence Ac-LKKTETQ

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin beta-4. Research describes sequestration of G-actin monomers, regulating the pool available for filament polymerisation and thereby influencing cytoskeletal reorganisation and cell motility. Studies document downstream effects on endothelial cell migration and angiogenesis, keratinocyte migration in dermal models, and stem cell recruitment to injury sites. Additional work reports anti-inflammatory activity, modulation of matrix metalloproteinase expression during remodelling, and progenitor cell recruitment to injury sites. The peptide's abundance in mammalian tissue is itself a recurring point in the mechanistic literature.

TB-500 has a substantial preclinical literature with a genuine, if limited, clinical component — including early-phase human trials in ocular and dermal wound research. Cardiac research has examined animal models for cardiomyocyte survival and repair following ischaemic injury. Corneal and ocular early-phase human trials have investigated epithelial wound healing endpoints. Dermal wound healing studies have examined keratinocyte migration and closure rate in skin models. Foundational cytoskeletal biology research has characterised actin sequestration and cell motility. Note: this compound is listed by anti-doping authorities and detection methods are established.

• 5 mg per application (one metered dose)
• 4 doses per pen (20 mg total)
• Synthetic actin-binding fragment (Ac-LKKTETQ) of thymosin beta-4
• Pre-filled sterile solution — no reconstitution step required

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

• For in-vitro laboratory and preclinical research only — not for human or animal administration
• Listed by WADA (World Anti-Doping Agency) — detection methods are established; relevant for studies involving competitive athlete samples
• Human clinical data extremely limited: early-phase ocular and dermal wound healing trials published but no large-scale safety studies
• Actin-sequestration mechanism: appropriate controls for cytoskeletal dynamics endpoints required

• No established human adverse effect profile from controlled trials
• Early-phase ocular (corneal epithelial) and dermal wound healing trials: generally well tolerated at studied doses
• Animal model preclinical studies: good tolerability; injection site reactions possible
• Anti-doping detection status: relevant where biological samples are also being studied for sports drug testing purposes

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.